Bristol Myers Squibb Stock Rises After Schizophrenia Drug Gets FDA Approval
Shares of Bristol Myers Squibb (BMY) rose Friday, a day after the Food and Drug Administration (FDA) approved the use of what the pharmaceutical firm called the first treatment for schizophrenia in...
Bristol-Myers Squibb: Unlocking Value With KarXT FDA Approval And Oncology Pipeline Progress
Bristol-Myers Squibb is rated a "Buy" for long-term investors due to the revenue potential of KarXT (Cobenfy) and advancements in its oncology portfolio. Despite recent financial setbacks, BMY's st...
Bristol Myers Stock Jumps. Why Approval for Its Schizophrenia Drug Is Ground Breaking.
The drug is one of an emerging class of drugs that has drawn the interest of large pharma companies.
Bristol-Myers Squibb stock jumps on schizophrenia drug approval
Bristol-Myers Squibb shares rose in premarket trade on Friday after the Food and Drug Administration approved a schizophrenia drug.
US drug regulator approves the first new schizophrenia drug in 30 years
The US Food and Drug Administration (FDA) has approved Cobenfy, the first new drug for schizophrenia in over 30 years, developed by Bristol Myers Squibb. Taken as a twice-daily pill, the treatment ...
Bristol Myers Squibb (BMY) Stock Dips While Market Gains: Key Facts
Bristol Myers Squibb (BMY) closed at $49.49 in the latest trading session, marking a -1% move from the prior day.
Bristol Myers Squibb Presents Landmark 10-Year Follow-Up Data from CheckMate -067 Which Showed Continued Durable Long-Term Survival Benefit with Op...
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #10year--Bristol Myers Squibb Presents Landmark 10-Year Follow-Up Data from CheckMate -067 Which Showed Continued Durable Long-Term Survival Benefit.
Got $200? 2 Healthcare Stocks to Buy and Hold Forever
Bristol Myers Squibb and Gilead Sciences are longtime healthcare leaders. Both have the innovative abilities needed to continue developing new drugs.
Bristol Myers Stock Rises 16% in 3 Months: Buy, Sell or Hold?
BMY's recent rally gives investors a ray of hope after the downturn earlier on in 2024. However, we advise investors not to be over-optimistic at this point and look before they leap.
Bristol Myers Squibb Dividend Yield Pushes Past 5%
In trading on Monday, shares of Bristol Myers Squibb were yielding above the 5% mark based on its quarterly dividend (annualized to $2.4), with the stock changing hands as low as $47.55 on the day....
2 Unstoppable Dividend Growth Stocks You Can Buy Now With $100
A bear market could be around the corner, but it probably won't stop Bristol Myers Squibb and Royalty Pharma from rapidly raising their dividend payouts. Bristol Myers Squibb has increased its divi...
Bristol-Myers Squibb: A Better Earnings Outlook, Stronger Momentum Heading Into 2025
Bristol-Myers Squibb delivered a significant earnings beat in Q2, driving shares up 20% since spring and boosting sector performance. Despite concerns about long-term EPS, strong Q2 results and imp...
Bristol Myers Squibb (BMY) Falls More Steeply Than Broader Market: What Investors Need to Know
Bristol Myers Squibb (BMY) closed at $49.80 in the latest trading session, marking a -0.32% move from the prior day.
2 No-Brainer Large-Cap Stocks to Buy With $500 Right Now
An investment in these two stocks could pay off handsomely over the next five to 10 years. Bristol Myers is an established healthcare business with a portfolio of blockbuster drugs.
Long-Term Follow-Up Data from Phase 3 Study of CAMZYOS® (mavacamten) Underscores Established Efficacy and Safety Profile in Patients with Symptomat...
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #CAMZYOS--Long-Term Follow-Up Data from Phase 3 Study of CAMZYOS® (mavacamten) Underscores Established Efficacy and Safety Profile in Patients.
Related Companies